> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Biogen Is Dropping Its Rights To Beam's FcRN Program, The Last Apellis Opt-In
- URL: https://www.bullished.co/biogen-is-dropping-its-rights-to-beams-fcrn-program-the-last-apellis-opt-in-6b628112/
- Published: 2026-11-03T13:46:44.000Z
- Updated: 2026-11-03T13:46:44.000Z
- Description: Beam's quarterly collaboration revenue fell to $0.3 million as Biogen moved to end its rights, effective December 2026.
- Author: Matteo Parrino
- Tags: Earnings, BEAM, Industry: Healthcare

Beam's [10-Q filed Tuesday](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526444455/beam-20260930.htm?ref=bullished.co) discloses that Biogen gave notice in September that it will give up its FcRN base editing rights as of December 2026\. The program was the only one Apellis, which Biogen bought in May, had opted into under its research deal with the gene-editing company.

## Apellis revenue dries up

Beam, which develops gene-editing medicines built on base editing, signed the Apellis research deal in June 2021 and received $75.0 million in upfront and near-term payments. Apellis opted into the FcRN program in 2025, paying a $3.8 million fee.

License and collaboration revenue was $307,000 in the third quarter, against $9.7 million a year earlier. Beam recorded no Apellis revenue in the quarter, versus $7.6 million in the year-earlier quarter. Beam's obligation to provide services under the agreement ended June 30, 2026, because Apellis did not extend it.

The [prior quarterly filing](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526331541/beam-20260630.htm?ref=bullished.co) mentioned a possible co-development deal with Apellis; the new 10-Q omits it, along with the alliance steering committee description.

## Cash, losses and the runway

Beam's net loss was $134.4 million for the quarter, or $1.28 per share, compared with $112.6 million a year earlier, according to its [earnings release](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526444454/beam-ex99%5F1.htm?ref=bullished.co). Cash and marketable securities fell to $1.0 billion from $1.2 billion at the end of 2025.

The 10-Q says that cash covers operations for at least 12 months. The earnings release says the runway reaches into mid-2029 only with an additional $200 million expected from the Sixth Street credit facility, assuming Beam meets the borrowing conditions.

The filing also shows Beam paid a $5.0 million development milestone during the quarter under a 2024 settlement tied to BEAM-102 and BEAM-302\. The company's market value was $2.7 billion in Tuesday morning data.

## What partner revenue is left

Beam's remaining partnered income leans on Eli Lilly, which can pay up to $350.0 million in development-stage payments under a 2023 agreement. Beam has received $50.0 million of that so far, including $25.0 million recognized in the first nine months of 2026.

The biggest near-term catalyst is a risto-cel biologics license application, an FDA approval request for its sickle cell therapy, which Beam expects as early as year-end 2026\. FDA acceptance of that filing would let Beam draw a first $100 million from Sixth Street.

Biogen's termination takes effect in December 2026, and the risto-cel filing is expected as early as year-end.

### Sources

- [10-Q Filing — Beam Therapeutics (BEAM)](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526444455/beam-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Beam Therapeutics (BEAM), Q2 FY2026 filed 2026-08-04 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526331541/beam-20260630.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, beam-ex99\_1.htm) — Beam Therapeutics, filed 2026-11-03](https://www.sec.gov/Archives/edgar/data/0001745999/000119312526444454/beam-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [Beam Therapeutics GAAP EPS of -$1.28 misses by $0.13, revenue of $0.31M (BEAM:NASDAQ)](https://seekingalpha.com/news/4663280-beam-therapeutics-gaap-eps-of-1%5F28-misses-by-0%5F13-revenue-of-0%5F31m?ref=bullished.co) — seekingalpha.com
- [Beam Therapeutics Inc. v. Whynot](https://www.law360.com/cases/6a885ee787b520253df778b6?ref=bullished.co) — law360.com
- [Plug-and-play gene therapy: FDA executes on vision that’s been in the works for years - BioSpace](https://www.biospace.com/fda/plug-and-play-gene-therapy-fda-executes-on-vision-thats-been-in-the-works-for-years?ref=bullished.co) — biospace.com
- [Beam Inc. (NYSE:BEAM) : Cases :: Law360](https://www.law360.com/companies/beam-inc/cases?ref=bullished.co) — law360.com
- [Beam Therapeutics Inc. v. Wang et al](https://www.law360.com/cases/6ab70ed953fb3a385b739436?ref=bullished.co) — law360.com